Estrogen receptor-alpha (ER), encoded by the ESR1 gene located on 6q25, is a nuclear transcription factor. Since it was reported in 2007 that more than 20% of breast cancers show ESR1 gene amplification, there has been considerable controversy about its frequency and clinical significance. The aim of this study was to assess the real and exact frequency and levels of ESR1 amplification in breast cancers. 
, Masafumi Inokuchi 2) , Shinichi Harada 3) , Johji Inazawa 4) , Ryousuke Tajiri 1) , Seiko Sawada-Kitamura 5) , Hiroko Ikeda 5) , Hiroko Kawashima 6) Introduction Estrogen receptor-alpha (ER) is as a nuclear transcription factor activated by estrogen to regulate the growth and differentiation of normal breast epithelial cells.
These pathways remain operative to varying degrees in breast cancers, and thus ER is a target for various endocrine therapies [1, 2] . ER is encoded by the estrogen receptor-alpha gene (ESR1) located on 6q25. In 2007, Holst et al. [3] reported that more than 20% of breast cancers showed ESR1 gene amplification, mainly based on FISH results using tissue microarrays. Furthermore, they suggested that the amplification of ESR1 is a frequent mechanism for ER overexpression, and that the amplification was significantly correlated to the response to anti-estrogen therapy. However, this was immediately disputed by other groups of researchers, because first, other FISH and chromogen in situ hybridization (CISH) studies using tissue microarrays [4, 5] detected amplification in less than 1.5% of breast cancers, and second, DNA extraction methods such as array comparative genomic hybridization (CGH) and quantitative PCR consistently detected very low frequencies (less than 3%) or no amplification [4, 6, 7] .
Since then, there has been heated discussion about the frequency and clinical significance of ESR1 amplification [8] [9] [10] . Recently, Moelans et al. also examined ESR1 amplification of breast carcinomas using multiplex ligation-dependent probe amplification (MLPA), and found that its amplification is rare and has poor concordance with the amplification detected by FISH and overexpression of ER [11] .
The major cause of the discordance between FISH and CISH studies might be the use of different (an automated or manual) scoring systems and/or different interpretations of the definition of 'amplification'. The used samples also could be another cause, because tissue microarrays used in previous FISH studies were made from isolated surgical specimens in which the size of each specimen was too small to observe background lesions or possible cancer heterogeneity. Furthermore, it is technically difficult to optimize FISH conditions for each specimen in an array [5] , and after the introduction of neo-adjuvant therapy, surgical materials may have therapeutic effects. MLPA is a new, high-resolution method for detecting copy number variations in genomic sequences [12] .
Moelans et al. have shown high concordance between the ERBB2 status of breast cancers detected by MLPA, CGH, FISH, and immunohistochemistry (IHC) [13] . Thus, in the present study, we performed FISH using whole sections of core needle biopsy specimens that were carefully fixed and processed to optimize FISH results, as well as imprinted cells obtained from fresh surgical specimens. In addition, we analyzed gene amplification by MLPA and compared the results with FISH results. In order to test the validity of the methodology, ERBB2 status was also examined by IHC, FISH, and MLPA.
Materials and Methods
Core needle biopsies, touch smears, and DNA samples Core needle biopsy specimens obtained from 106 breast carcinomas were immediately fixed in 10% buffered formalin for no longer than overnight and embedded in paraffin according to standard procedures. Serial sections (4 μm) placed onto MAS-coated glass slides TM (Matsunami, Tokyo, Japan) were used for hematoxylin-eosin staining, IHC detection of ER and ERBB2, and FISH analysis. The tumors consisted of 14 ductal carcinomas in situ, 87 invasive ductal carcinomas, and 5 invasive lobular carcinomas. Two patients had bilateral cancers. From surgery on 49 patients, small fragments of cancer tissue (51) and adjacent non-neoplastic tissues (37) were trimmed. The cancer tissues were touched on MAS-coated slides TM , which were dried and fixed immediately in metacarn solution (methanol/acetic acid, 3:1) and stored in a freezer until FISH analysis. From the rest of the fresh samples, high molecular weight DNA was prepared by protease K (Boehringer Mannheim, Mannheim, Germany) digestion and phenol/chloroform extraction as described elsewhere [14] and used for MLPA analysis. This laboratory study was approved by the Institutional Review Board at the Kanazawa University Hospital (Approval No. 181), and written informed consent was obtained from all patients.
Cell lines and normal lymphocytes
The breast cancer cell line MCF-7 expressing ER, and cell lines UACC-812 and MDA-361 that do not express ER [15] St. Gallen, Switzerland [16] . For the evaluation of ERBB2 positivity, each tumor was scored using the four-tier system recommended by the American Society of Clinical Oncology (ASCO) for IHC of ERBB2 [17] and reviewed by two of the authors. First, we performed FISH using formalin-fixed paraffin-embedded (FFPE) tissues and imprinted cells with standard methods as described elsewhere [18] without using RNase A digestion. The FISH protocols for imprinted cancer and cultured cells were the same as for FFPE tissues, except protein digestion was made by 0.25 mg/ml pepsin at 37°C for 10 min, and prehybridization fixation was by 1% formaldehyde at room temperature for 5 min. Second, FISH with RNase A treatment was performed by incubating slides with RNase A (100 micro g/ml in 2XSSC) at 37°C for 30 min before hybridization.
When necessary, imprinted cells or tissue sections were submitted to digestion with RNase A or with 1U/ml of DNase I for 10 min at 37°C after the first standard FISH [19] . [11, 12, 20] .
Results

IHC
Seventy-eight of a total of 106 cases (74%) were ER-positive, and 28 (26%) cases were negative. The populations of positive cells in each tumor were more than 80% in 64 tumors and 10-80% in 14 tumors. There were no significant differences between the positive frequencies of DCIS (71%, 10/14), IDC (75%, 65/87), and ILC (60%, 3/5). In non-cancerous breast tissues, ER staining was found heterogeneously in ductal and acinal cells ranging from 2 to 30%. ERBB2 overexpression was found in 27 tumors (12 of 2+ and 15 of 3+ tumors). Figure 5C . The ESR1/centromere 6 signal patterns found in more than 40% of cancer nuclei were considered as predominant subpopulations and are shown in Table 1 . The amplification ratios detected for biopsy specimens of the 51 cases in which both FISH on FFPE tissues and FISH on imprinted cells were performed are also shown in Table 1 . Three tumors (Cases 1-3) had predominant subpopulations of cancer cells with an additional one to three ESR1 signals as shown in Figure 5B ; thus, they were considered to be tumors with low-level amplifications. However, in two of the three (Cases 2 and 3) this low-level amplification was not detected by FISH on the biopsy specimens as shown by the amplification ratios of 1.5 and 1.6, respectively. in HSRs; thus, we and others suggest that it should be called "HSR-type" and that it be considered a criterion of gene amplification in FISH analysis of ERBB2 status [3, 21, 22] . In the present FISH study, variously extended ESR1 signals were found in ER-expressing cells. Some of them were indistinguishable from 'HSR-type' signals of ERBB2 found in breast cancers, and could be considered to represent gene amplification in HSRs. In fact, in previous studies reporting that gene amplification of ESR1 occurs in more than 20% of breast cancers, these FISH images seem to be the basis for their high reported frequencies [3, 8] . However, the present study showed that this 'HSR-like' signal is RNase A-sensitive and DNase I-resistant; thus, the hybridization partner proved to be RNA.
Concentrations of nuclear RNAs are found by FISH at the transcription sites of such actively transcribed genes as collagen type 1, [25, 26] ,-actin [27] , and dystrophine [28] , and are studied in normal and mutant cells to discern the interrelationship of RNA metabolism and nuclear structure [25, 26] . At the present time, two possibilities that are not mutually exclusive explain nuclear RNAs found by FISH: one is that mRNA forms a "track" that moves away from the gene [26] , and the other is that nascent transcripts are attached to the gene-like "trees" [28] . In this respect, our FISH results using two differently labeled probes corresponding to the non-overlapping 5' and 3'-end portions of the ESR1 gene are very informative, because the two fluorescences representing two portions were not mixed, but were found abutting each other. If the accumulated RNAs were mature mRNAs, then due to their much reduced sizes (less than one forty-fifth) compared to that of the gene, the signals would have been much weaker, and furthermore, the assembly of molecules containing two portions simultaneously would have made the two color signals intermingle as depicted in Figure 4A . Therefore, our results strongly suggest that the RNA represents newly synthesized nascent RNA molecules extending from the gene as depicted in Figure 4B . It is also possible that this RNA is derived from another gene being transcribed in the opposite direction. For example, it is known that a stable transcript produced from NCYM, MYCN anti-sense DNA, is cotranscribed with MYCN [29] . By searching databases, we found a 258-base transcript [30] that is located on the opposite DNA strand of ESR1. However, it is not possible that this small transcript caused the HSR-like signals found in this study.
Unfortunately, FISH analysis using clinical specimens does not have high enough resolving power to further clarify the molecular kinetic events. Smith et al. reported that simultaneous hybridization of differently labeled probes for different non-overlapping sequences within the dystrophine gene, as in our experiment, produced non-overlapping fluorescences in a single-molecular FISH study [28] . They explained the result by 'cotranscriptional splicing', that is, more 5' introns are spliced out of the nascent RNA molecules before the 3' end of the RNA is transcribed; thus, the two sequences of the transcript do not exist simultaneously. In any case, there was a positive correlation between ER-overexpression detected by IHC and the amount of this nuclear RNA detected by FISH on a nucleus-by-nucleus basis. Thus, this protein overexpression is thought to come from active RNA transcription from ESR1 genes, which occurs by a different mechanism than gene amplification.
RNA is most vulnerable to degradation during the usual process of making pathological specimens from surgical materials. In fact, in standard protocols of FISH using FFPE tissues, RNase treatment is not mandatory [31] and is only recommended to reduce background RNA staining in FISH using cultured cells [32] . The core needle biopsies used in the present study minimized the duration of pre-fixative steps, and thus may preserve RNA well. FISH on touch smear specimens had fewer extended signals than those found in FFPE tissues in several cases. This is well explained by the fact that the metacarn fixative does not preserve RNA well [33] . However, in spite of being similarly prepared, and the supposedly active RNA transcription, transcripts of ERBB2
were not detected in ERBB2-overexpressing cells. Therefore, RNA retention probably depends on the properties of individual transcripts [33, 34] . In fact, in our previous DNA-DNA FISH studies targeting EGFR, ERBB2, and MYC, etc., we have never found a case where transcript RNA had a significant effect on interpretations FISH results [18, 22, 35] .
When the results of MLPA and two FISH analyses were compared, a gain of ESR1 was found in five tumors by MLPA (Cases 1-5), and the FISH using imprinted cells revealed that three (Cases 1-3) had additional copies of ESR1, which were evaluated to be low-level amplification. FISH on FFPE tissues, however, could not detect this low-level amplification in two of them (Cases 2 and 3) . This is because FISH on imprinted cells, different from FISH on FFPE tissues, had no effects on nuclear truncation, and thus more precise enumeration of the signals is possible. The sensitivity and specificity of the 'gain' by MLPA against amplification detected by FISH using imprinted cells, if the present cut-off value of 1.3 is used, are 100% and 96%, respectively, and both would be 100% if a cut-off value of 1.4 is used.
In the analysis of ERBB2, the six tumors with the highest peak values (Cases 9, 27, 33, 34, 41, and 48) were those with high-level amplification in FISH using FFPE tissues.
Both the sensitivity and specificity of MLPA against FISH were 100%. Thus, MLPA is a useful tool to detect gene amplification of ESR1 and ERBB2, especially when an appropriate cut-off value is chosen. Moelans et al. performed MLPA for 135 breast cancers using the same kit and the same analysis software as in the present study, but with DNAs extracted from FEPE tissues, and found gene amplification of ESR1 in three (2%) with marginal peak values of no more than 2.1 and a gain in 8 (6%) [11] . We do not consider our ESR1 gain rate of 5.9% (3/51) to be fundamentally different from the frequency of Moelans et al. This low-level amplification was not correlated with ER overexpression, which mostly occurs by a different mechanism than gene amplification.
Consequently, the consistent results of IHC, FISH, and MLPA in the present study show that the amplification of ESR1 in breast carcinoma occurs as low-level amplification, and in addition, at a low frequency of 5.9%. We believe that the results in our present study settle the long-standing debate concerning gene amplification of ESR1 in breast carcinoma. 
